Clinical trials in Rennes – page 4

868 clinical trials in Rennes, France across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Rennes at a glance

868

clinical trials

Research sites4

Quick filters

868 trials in Rennes

Open in trial search

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

France

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Small cell lung cancer

Recruiting

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo

A Study of ABBV-706 to Assess Safety and Efficacy Compared with Standard Drug Combination in Adults with Relapsed or Refractory Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Topotecan
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Institut Gustave Roussy

Contact Research Centre

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo

Rinatabart Sesutecan plus bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Genmab A/S

Contact Research Centre

Colorectal cancer+2

Recruiting

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo

Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Incyte Corp.

Contact Research Centre

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:AZD0901
Sponsor:AstraZeneca AB

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Metabolic dysfunction-associated steatohepatitis

Recruiting

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Mantle cell lymphoma

Recruiting

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug

Phase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Rituximab

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Rennes

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancers, breast cancer, and hematologic malignancies. Studies are evaluating novel therapeutic approaches including immunotherapy combinations and targeted treatments.

Advanced squamous cell carcinoma treatments
Triple-negative breast cancer interventions
Acute myeloid leukemia therapies

Multiple research centers are investigating breakthrough treatments for various stages of cancer progression.

02 Neurological Disorders

Comprehensive research into multiple sclerosis and movement disorders, utilizing advanced imaging techniques and innovative therapeutic approaches.

MS treatment optimization
Essential tremor management
Neuroinflammation imaging

Studies are focused on improving patient outcomes through targeted interventions and precision medicine approaches.

03 Critical Care Medicine

Investigating new approaches in postoperative care and immunotherapy for critical care patients, with emphasis on patient comfort and infection prevention.

Pain management protocols
Immune system modulation
Post-surgical care optimization

Research aims to enhance recovery outcomes and reduce complications in intensive care settings.

Back to France All countries